These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 27368114)

  • 21. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    Lightfoot M; Montemorano L; Bixel K
    Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    Mohyuddin GR; Aziz M; Britt A; Wade L; Sun W; Baranda J; Al-Rajabi R; Saeed A; Kasi A
    BMC Cancer; 2020 Jun; 20(1):507. PubMed ID: 32493233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploiting replication gaps for cancer therapy.
    Cong K; Cantor SB
    Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
    Hottiger MO
    Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
    Francica P; Rottenberg S
    Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
    Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 31. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
    Rescigno P; Chandler R; de Bono J
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):339-343. PubMed ID: 29979319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    Lee JM; Ledermann JA; Kohn EC
    Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
    Hu J; Liang P; Jin D; Fan R; Xie X; Liu C; Jiang Q; Gao L
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):717-723. PubMed ID: 35679134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
    Ning J; Wakimoto H
    Trends Cancer; 2020 Feb; 6(2):147-159. PubMed ID: 32061304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.